Astellas said it has removed a Phase 1 cancer asset as well as a small molecule that came from its Mitobridge acquisition.
After hitting a speed bump in its first attempt at developing a gene therapy for Friedreich’s ataxia, Astellas is ready to put a new version in the clinic.
The threat of low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has moved a step closer after a court recommended denying an injunction on the launch of generics.
Astellas writes down another piece of its Audentes gene therapy acquisition
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US...
CytomX Therapeutics, Inc. has achieved a second clinical candidate nomination under its TCB collaboration with Astellas Pharma US, Inc., triggering a $5 million milestone payment to CytomX. CytomX and Astellas are collaborating on multiple conditionally activated TCB programs with CytomX eligible to receive additional future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets
Endometriosis Global Clinical Trials Review 2024, Featuring AbbVie, Bayer, Ferring Holding, Neurocrine Biosciences, Sumitomo, Takeda Pharmaceutical, Kissei Pharmaceutical, Pfizer and Astellas Pharma - ResearchAndMarkets.com